INS and type 1 diabetes mellitus: The findings from this study may differ from those reported in randomized controlled clinical trials for medication classes such as SLGT-2 inhibitors, amylin analogs, GLP-1 receptor analogs, and DPP4 inhibitors, which have demonstrated clinically significant and positive results on reducing body weight, total daily insulin needs, and A1C among patients with type 1 diabetes [7,8,9,10,11].